CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter’s Vraylar sees positive results for bipolar depression
Five things for pharma marketers to know: Wednesday, February 22, 2017
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
Five things for pharma marketers to know: Thursday, May 28
The FBI is investigating Johnson & Johnson’s morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
Five things for pharma marketers to know: Wednesday, March 25
Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute
Five things for pharma marketers to know: Tuesday, March 10
HCV drugs and other specialty medications drove a 13% increase in last year’s prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera’s drug that can reduce double chins.
Five things for pharma marketers to know: Thursday, February 19
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for “drug reaction reviews”; Roche skin-cancer drug receives Priority Review.
FDA approves Amgen leukemia immunotherapy
December 3, 2014
6:30 pm
Amgen’s Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.